Thermo Fisher Raises 2026 Revenue and Earnings Guidance Following Strong Q1

Thermo Fisher Scientific (TMO) has signaled confidence in its growth trajectory by raising its financial outlook for 2026. The company reported a robust start to the year, indicating that its core end markets are performing in line with internal expectations. The upward revision comes as the life sciences giant continues to expand its operational capabilities. A key driver in the company's strategic growth has been the completion of the Clario acquisition, which strengthens its portfolio in clinical trial technology and data management. For the 2026 fiscal year, Thermo Fisher now projects adjusted earnings per share (EPS) to fall between $24.64 and $25.12. On the top line, the company has raised its revenue guidance to a range of $47.3 billion to $48.1 billion. These projections suggest a stable recovery or growth phase in the biotechnology and pharmaceutical research sectors. Investors typically view raised guidance as a bullish signal regarding demand for laboratory equipment and diagnostic services.